Eli Lilly & Co.’s Inc.’s stock soared 13% in premarket trade Thursday, after the drug maker reported positive results from a late-stage trial of an oral GLP-1 treatment for Type 2 diabetes.

(Reuters) -Eli Lilly said on Thursday its experimental pill, orforglipron, led to a weight loss of nearly 8% at the highest ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

Injectable drugs require refrigeration when they are stored or transported, and the pill potentially opens up the market ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

The results bring Eli Lilly’s pill orforglipron one step closer to becoming a new, needle-free alternative in the booming ...

U.S. pharma giant Eli Lilly And Co (NYSE:LLY) announced the launch of its popular weight loss drug Mounjaro (tirzepatide) in ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

Clinical results of a GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs.

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. The phase 3 ...

The threat of import duties has already spurred drugmakers to accelerate shipments to the U.S. and warehouse supplies, which analysts say will protect their 2025 financial outlooks and take the pressu ...